MRI-based radiomic features for identifying recurrent prostate cancer after proton radiation therapy.
MRI
prostate cancer
proton therapy
radiomics
recurrence
Journal
Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176
Informations de publication
Date de publication:
26 Feb 2024
26 Feb 2024
Historique:
revised:
05
01
2024
received:
16
10
2023
accepted:
16
01
2024
medline:
27
2
2024
pubmed:
27
2
2024
entrez:
27
2
2024
Statut:
aheadofprint
Résumé
Magnetic Resonance Imaging (MRI) evaluation of recurrent prostate cancer (PCa) following proton beam therapy is challenging due to radiation-induced tissue changes. This study aimed to evaluate MRI-based radiomic features so as to identify the recurrent PCa after proton therapy. We retrospectively studied 12 patients with biochemical recurrence (BCR) following proton therapy. Two experienced radiologists identified prostate lesions from multi-parametric MRI (mpMRI) images post-proton therapy and marked control regions of interest (ROIs) on the contralateral side of the prostate gland. A total of 210 radiomic features were extracted from lesions and control regions on the T2-weighted (T2WI) and Apparent Diffusion Coefficient (ADC) image series. Recursive Feature Elimination with Cross-Validation method (RFE-CV) was used for feature selection. A Multilayer Perceptron (MLP) neural network was developed to classify three classes: cancerous, benign, and healthy tissue. The 12-core biopsy results were used as the gold standard for the segmentations. The classifier performance was measured using specificity, sensitivity, the area under receiver operating characteristic curve (AUC), and other statistical indicators. Based on biopsy results, 10 lesions were identified as PCa recurrence while eight lesions were confirmed to be benign. Ten radiomic features (10/210) were selected to build the multi-class classifier. The radiomics classifier gave an accuracy of 0.83 in identifying cancerous, benign, and healthy tissue with a sensitivity of 0.80 and specificity of 0.85. The model yielded an AUC of 0.87, 95% CI [0.72-1.00] in differentiating cancer from the benign and healthy tissues. Our proof-of-concept study demonstrates the potential of using radiomic features as part of the differential diagnosis of PCa on mpMRI following proton therapy. The results need to be validated in a larger cohort.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14293Subventions
Organisme : University of Florida College of Medicine-Jacksonville Launchpad Initiative
Informations de copyright
© 2024 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine.
Références
Potretzke TA, Froemming AT, Gupta RT. Post-treatment prostate MRI. Abdom Radiol (NY). 2020;45(7):2184-2197. doi:10.1007/s00261-019-02348-x
Barchetti F, Panebianco V. Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy. Biomed Res Int. 2014;2014:316272. doi:10.1155/2014/316272
Schmidt-Hegemann NS, Stief C, Kim TH, et al. Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis. J Nucl Med. 2019;60(2):227-233. doi:10.2967/jnumed.118.212563
Takagi M, Demizu Y, Terashima K, et al. Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med-Us. 2017;6(10):2234-2243. doi:10.1002/cam4.1159
Dinis Fernandes C, Ghobadi G, van der Poel HG, et al. Quantitative 3-T multi-parametric MRI and step-section pathology of recurrent prostate cancer patients after radiation therapy. Eur Radiol. 2019;29(8):4160-4168. doi:10.1007/s00330-018-5819-y
Dinis Fernandes C, Dinh CV, Walraven I, et al. Biochemical recurrence prediction after radiotherapy for prostate cancer with T2w magnetic resonance imaging radiomic features. Phys Imaging Radiat Oncol. 2018;7:9-15. doi:10.1016/j.phro.2018.06.005
Bazargani S, Feibus AH, Elshafei A, et al. Magnetic resonance imaging radiomic features for recurrent prostate cancer following proton radiation therapy-a pilot study. Urol Oncol. 2023;41(3):145.e1-145.e5. doi:10.1016/j.urolonc.2022.10.007
Gaur S, Turkbey B. Prostate MR imaging for posttreatment evaluation and recurrence. Urol Clin North Am. 2018;45(3):467-479. doi:10.1016/j.ucl.2018.03.011
Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278(2):563-577. doi:10.1148/radiol.2015151169
Calimano-Ramirez LF, Virarkar MK, Hernandez M, et al. MRI-based nomograms and radiomics in presurgical prediction of extraprostatic extension in prostate cancer: a systematic review. Abdom Radiol. 2023;48(7):2379-2400. doi:10.1007/s00261-023-03924-y
Cutaia G, La Tona G, Comelli A, et al. Radiomics and prostate MRI: current role and future applications. J Imaging. 2021;7(2):1-13. doi:10.3390/jimaging7020034
Gholizadeh N, Simpson J, Ramadan S, et al. Voxel-based supervised machine learning of peripheral zone prostate cancer using noncontrast multiparametric MRI. J Appl Clin Med Phys. 2020;21(10):179-191. doi:10.1002/acm2.12992
Hou Y, Bao ML, Wu CJ, Zhang J, Zhang YD, Shi HB. A radiomics machine learning-based redefining score robustly identifies clinically significant prostate cancer in equivocal PI-RADS score 3 lesions. Abdom Radiol (NY). 2020;45(12):4223-4234. doi:10.1007/s00261-020-02678-1
Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965-974. doi:10.1016/j.ijrobp.2006.04.029
Baumann M, Mozer P, Daanen V, Troccaz J. Prostate biopsy assistance system with gland deformation estimation for enhanced precision. Med Image Comput Comput Assist Interv. 2009;12(Pt 1):67-74. doi:10.1007/978-3-642-04268-3_9
Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006;31(3):1116-1128. doi:10.1016/j.neuroimage.2006.01.015
Scalco E, Belfatto A, Mastropietro A, et al. T2w-MRI signal normalization affects radiomics features reproducibility. Med Phys. 2020;47(4):1680-1691. doi:10.1002/mp.14038
Ogura A, Tamura T, Ozaki M, et al. Apparent diffusion coefficient value is not dependent on magnetic resonance systems and field strength under fixed imaging parameters in brain. J Comput Assist Tomo. 2015;39(5):760-765. doi:10.1097/Rct.0000000000000266
Ligero M, Jordi-Ollero O, Bernatowicz K, et al. Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis. Eur Radiol. 2021;31(3):1460-1470. doi:10.1007/s00330-020-07174-0
van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77(21):e104-e107. doi:10.1158/0008-5472.CAN-17-0339
Zwanenburg A, Vallieres M, Abdalah MA, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328-338. doi:10.1148/radiol.2020191145
Guyon I, Weston J, Barnhill S, Vapnik V. Gene selection for cancer classification using support vector machines. Mach Learn. 2002;46(1-3):389-422. doi:10.1023/A:1012487302797
Cortes C, Vapnik V. Support-vector networks. Mach Learn. 1995;20(3):273-297. doi:10.1023/A:1022627411411
Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: machine learning in Python. J Mach Learn Res. 2011;12:2825-2830.
Bishop CM. Neural networks for pattern recognition. Clarendon Press; Oxford University Press; 1995. xvii, 482 p.
Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767-1777. doi:10.1056/NEJMoa1801993
Chen T, Zhang Z, Tan S, et al. MRI based radiomics compared with the PI-RADS V2.1 in the prediction of clinically significant prostate cancer: biparametric vs multiparametric MRI. Front Oncol. 2021;11:792456. doi:10.3389/fonc.2021.792456
Hectors SJ, Cherny M, Yadav KK, et al. Radiomics features measured with multiparametric magnetic resonance imaging predict prostate cancer aggressiveness. J Urol. 2019;202(3):498-505. doi:10.1097/JU.0000000000000272
Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and Data System Version 2.1: 2019 update of prostate imaging reporting and Data System Version 2. Eur Urol. 2019;76(3):340-351. doi:10.1016/j.eururo.2019.02.033